Liposomes containing monophosphoryl lipid A and QS-21 serve as an effective adjuvant for soluble circumsporozoite protein malaria vaccine FMP013. (Q38735533)

From Wikidata

Jump to navigation Jump to search

scientific article published on 05 June 2017

Language	Label	Description	Also known as
English	Liposomes containing monophosphoryl lipid A and QS-21 serve as an effective adjuvant for soluble circumsporozoite protein malaria vaccine FMP013.	scientific article published on 05 June 2017

Statements

scholarly article

1 reference

Europe PubMed Central

6 September 2017

Liposomes containing monophosphoryl lipid A and QS-21 serve as an effective adjuvant for soluble circumsporozoite protein malaria vaccine FMP013. (English)

1 reference

Europe PubMed Central

6 September 2017

1 reference

based on heuristic

inferred from title

malaria vaccine

1 reference

based on heuristic

inferred from title

author name string

Zoltan Beck

2

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28596090%20AND%20SRC:MED&resulttype=core&format=json

31 May 2020

Fanta Kalle

4

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28596090%20AND%20SRC:MED&resulttype=core&format=json

31 May 2020

Keith J Limbach

5

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28596090%20AND%20SRC:MED&resulttype=core&format=json

31 May 2020

Maureen E Stefaniak

6

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28596090%20AND%20SRC:MED&resulttype=core&format=json

31 May 2020

Noelle B Patterson

7

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28596090%20AND%20SRC:MED&resulttype=core&format=json

31 May 2020

Elke S Bergmann-Leitner

8

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28596090%20AND%20SRC:MED&resulttype=core&format=json

31 May 2020

Norman C Waters

9

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28596090%20AND%20SRC:MED&resulttype=core&format=json

31 May 2020

Gary R Matyas

10

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28596090%20AND%20SRC:MED&resulttype=core&format=json

31 May 2020

Carl R Alving

11

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28596090%20AND%20SRC:MED&resulttype=core&format=json

31 May 2020

Sheetij Dutta

12

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28596090%20AND%20SRC:MED&resulttype=core&format=json

31 May 2020

language of work or name

0 references

publication date

5 June 2017

1 reference

Europe PubMed Central

6 September 2017

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28596090%20AND%20SRC:MED&resulttype=core&format=json

31 May 2020

35

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28596090%20AND%20SRC:MED&resulttype=core&format=json

31 May 2020

3865-3874

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28596090%20AND%20SRC:MED&resulttype=core&format=json

31 May 2020

31

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28596090%20AND%20SRC:MED&resulttype=core&format=json

31 May 2020

The malaria circumsporozoite protein has two functional domains, each with distinct roles as sporozoites journey from mosquito to mammalian host

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.05.070

7 January 2021

Function of region I and II adhesive motifs of Plasmodium falciparum circumsporozoite protein in sporozoite motility and infectivity

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.05.070

7 January 2021

Activity of human volunteer sera to candidate Plasmodium falciparum circumsporozoite protein vaccines in the inhibition of sporozoite invasion assay of human hepatoma cells and hepatocytes.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.05.070

7 January 2021

Randomized, double-blind, phase 2a trial of falciparum malaria vaccines RTS,S/AS01B and RTS,S/AS02A in malaria-naive adults: safety, efficacy, and immunologic associates of protection

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.05.070

7 January 2021

A preliminary evaluation of a recombinant circumsporozoite protein vaccine against Plasmodium falciparum malaria. RTS,S Malaria Vaccine Evaluation Group

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.05.070

7 January 2021

Efficacy and safety of RTS,S/AS01 malaria vaccine with or without a booster dose in infants and children in Africa: final results of a phase 3, individually randomised, controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.05.070

7 January 2021

Fractional Third and Fourth Dose of RTS,S/AS01 Malaria Candidate Vaccine: A Phase 2a Controlled Human Malaria Parasite Infection and Immunogenicity Study

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.05.070

7 January 2021

Efficacy and safety of the RTS,S/AS01 malaria vaccine during 18 months after vaccination: a phase 3 randomized, controlled trial in children and young infants at 11 African sites

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.05.070

7 January 2021

A phase 3 trial of RTS,S/AS01 malaria vaccine in African infants

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.05.070

7 January 2021

First results of phase 3 trial of RTS,S/AS01 malaria vaccine in African children

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.05.070

7 January 2021

Seven-Year Efficacy of RTS,S/AS01 Malaria Vaccine among Young African Children

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.05.070

7 January 2021

Genetic Diversity and Protective Efficacy of the RTS,S/AS01 Malaria Vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.05.070

7 January 2021

Towards an RTS,S-based, multi-stage, multi-antigen vaccine against falciparum malaria: progress at the Walter Reed Army Institute of Research.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.05.070

7 January 2021

Assessment of Pfs25 expressed from multiple soluble expression platforms for use as transmission-blocking vaccine candidates

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.05.070

7 January 2021

Safety and High Level Efficacy of the Combination Malaria Vaccine Regimen of RTS,S/AS01B With Chimpanzee Adenovirus 63 and Modified Vaccinia Ankara Vectored Vaccines Expressing ME-TRAP.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.05.070

7 January 2021

Public health challenges and prospects for malaria control and elimination

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.05.070

7 January 2021

Reversible Conformational Change in the Plasmodium falciparum Circumsporozoite Protein Masks Its Adhesion Domains

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.05.070

7 January 2021

The N-terminal domain of Plasmodium falciparum circumsporozoite protein represents a target of protective immunity

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.05.070

7 January 2021

Proteolytic Cleavage of the Plasmodium falciparum Circumsporozoite Protein Is a Target of Protective Antibodies

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.05.070

7 January 2021

IgG2 antibodies against a clinical grade Plasmodium falciparum CSP vaccine antigen associate with protection against transgenic sporozoite challenge in mice

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.05.070

7 January 2021

Beyond empiricism: informing vaccine development through innate immunity research

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.05.070

7 January 2021

TLR signaling pathways

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.05.070

7 January 2021

Identification of QS-21 as an Inflammasome-activating Molecular Component of Saponin Adjuvants

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.05.070

7 January 2021

Cutting edge: inflammasome activation by alum and alum's adjuvant effect are mediated by NLRP3.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.05.070

7 January 2021

AS04, an aluminum salt- and TLR4 agonist-based adjuvant system, induces a transient localized innate immune response leading to enhanced adaptive immunity

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.05.070

7 January 2021

Differential immune responses to HIV-1 envelope protein induced by liposomal adjuvant formulations containing monophosphoryl lipid A with or without QS21.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.05.070

7 January 2021

Oil-in-water liposomal emulsions for vaccine delivery

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.05.070

7 January 2021

Detection of liposomal cholesterol and monophosphoryl lipid A by QS-21 saponin and Limulus polyphemus amebocyte lysate.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.05.070

7 January 2021

Transgenic parasites stably expressing full-length Plasmodium falciparum circumsporozoite protein as a model for vaccine down-selection in mice using sterile protection as an endpoint

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.05.070

7 January 2021

Head-to-Head Comparison of Soluble vs. Qβ VLP Circumsporozoite Protein Vaccines Reveals Selective Enhancement of NANP Repeat Responses

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.05.070

7 January 2021

Adenovirus 5-vectored P. falciparum vaccine expressing CSP and AMA1. Part A: safety and immunogenicity in seronegative adults

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.05.070

7 January 2021

Identification of minimal human MHC-restricted CD8+ T-cell epitopes within the Plasmodium falciparum circumsporozoite protein (CSP)

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.05.070

7 January 2021

SPICE: exploration and analysis of post-cytometric complex multivariate datasets

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.05.070

7 January 2021

The Economics of Malaria Vaccine Development

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.05.070

7 January 2021

Cell-mediated immune responses to a varicella-zoster virus glycoprotein E vaccine using both a TLR agonist and QS21 in mice

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.05.070

7 January 2021

Montanide ISA 720 and 51: a new generation of water in oil emulsions as adjuvants for human vaccines

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.05.070

7 January 2021

Selection of an adjuvant for vaccination with the malaria antigen, MSA-2.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.05.070

7 January 2021

Overcoming antigenic diversity by enhancing the immunogenicity of conserved epitopes on the malaria vaccine candidate apical membrane antigen-1.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.05.070

7 January 2021

Safety and enhanced immunogenicity of a hepatitis B core particle Plasmodium falciparum malaria vaccine formulated in adjuvant Montanide ISA 720 in a phase I trial

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.05.070

7 January 2021

Safety and immunogenicity of a three-component blood-stage malaria vaccine (MSP1, MSP2, RESA) against Plasmodium falciparum in Papua New Guinean children

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.05.070

7 January 2021

Rhesus macaque and mouse models for down-selecting circumsporozoite protein based malaria vaccines differ significantly in immunogenicity and functional outcomes

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.05.070

7 January 2021

Controlled human malaria infection

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.05.070

7 January 2021

A Sporozoite- and Liver Stage-expressed Tryptophan-rich Protein Plays an Auxiliary Role in Plasmodium Liver Stage Development and Is a Potential Vaccine Candidate

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.05.070

7 January 2021

Full-length Plasmodium falciparum circumsporozoite protein administered with long-chain poly(I·C) or the Toll-like receptor 4 agonist glucopyranosyl lipid adjuvant-stable emulsion elicits potent antibody and CD4+ T cell immunity and protection in mi

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.05.070

7 January 2021

Sporozoite neutralizing antibodies elicited in mice and rhesus macaques immunized with a Plasmodium falciparum repeat peptide conjugated to meningococcal outer membrane protein complex

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.05.070

7 January 2021

Efficacy of the Herpes Zoster Subunit Vaccine in Adults 70 Years of Age or Older

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.05.070

7 January 2021

Liposomal malaria vaccine in humans: a safe and potent adjuvant strategy

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.05.070

7 January 2021

Montanide ISA 720 vaccines: quality control of emulsions, stability of formulated antigens, and comparative immunogenicity of vaccine formulations

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.05.070

7 January 2021

A human phase 1 vaccine clinical trial of the Plasmodium falciparum malaria vaccine candidate apical membrane antigen 1 in Montanide ISA720 adjuvant

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.05.070

7 January 2021

Comparative cost models of a liquid nitrogen vapor phase (LNVP) cold chain-distributed cryopreserved malaria vaccine vs. a conventional vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.05.070

7 January 2021

Progress with Plasmodium falciparum sporozoite (PfSPZ)-based malaria vaccines

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.05.070

7 January 2021

P. falciparum and P. vivax Epitope-Focused VLPs Elicit Sterile Immunity to Blood Stage Infections

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.05.070

7 January 2021

A nonadjuvanted polypeptide nanoparticle vaccine confers long-lasting protection against rodent malaria

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.05.070

7 January 2021

Efficacy of an adjuvanted herpes zoster subunit vaccine in older adults

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.05.070

7 January 2021

Phase I Clinical Trial of a Recombinant Malaria Vaccine Consisting of the Circumsporozoite Repeat Region of Plasmodium Falciparum Coupled to Hepatitis B Surface Antigen

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.05.070

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/J.VACCINE.2017.05.070

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28596090%20AND%20SRC:MED&resulttype=core&format=json

31 May 2020

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28596090%20AND%20SRC:MED&resulttype=core&format=json

31 May 2020

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q38735533&oldid=1877503149"